Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study

University of Bern767 enrolled

Overview

This study will investigate the types of HPV in samples from women with cervical pre-cancer and cancer and gather information to help investigate the impact of HPV vaccination in Switzerland.

Study Type

OBSERVATIONAL

Enrollment

767

Conditions

Cervical Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Participant is literate in German, French, Italian or English. * Female, aged 18 years or above. * Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix. * Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino. Exclusion Criteria: * None

Locations (10)

Viollier AG

Allschwil, Basel-Landschaft, Switzerland

Universitätsspital Basel

Basel, Switzerland

Viollier Weintraub SA

Geneva, Switzerland

HUG - Hôpitaux Universitaires de Genève

Geneva, Switzerland

Outcomes

Primary Outcomes

Human papillomavirus presence and type

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.